Pharmaceutical Executive

Official Twitter account for Pharmaceutical Executive, a digital and print magazine offering news and opinions, analysis, features and executive profiles.

[Pharmaceutical Executive @PharmExec]

🚨Our March issue is LIVE🚨
Learn about immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics in our cover profile🔷 Sourcing, nurturing, and retaining talent🔷Making HCP analytics actually work for commercial teams🔷and much more right here➡️https://t.co/OhroSxYKFH

[Pharmaceutical Executive @PharmExec]

Scaling a pharma or biotech business comes down to one thing: talent.

Elaine Ferguson of Inizio Medical breaks down why connecting & developing talent drives sustainable growth.

Hear more here ➡️ https://t.co/6yRd1yvs7D

#Leadership #TalentDevelopment

[Pharmaceutical Executive @PharmExec]

AI is reshaping drug development & how FDA reviews it. The final Fault Lines Peer Exchange closes with what pharma boards need to know next: https://t.co/n9SS8L0i80

#PharmaExec

[Pharmaceutical Executive @PharmExec]

The FDA's peptide rulemaking is stalling.

An advisory panel already recommended 6 peptides for compounding, but enforcement is already cracking down on unapproved sellers.

Free sign-up, then read more here ➡️ https://t.co/4Fp7Z9snSr

#PharmExec #peptides #compounding

[Pharmaceutical Executive @PharmExec]

Our 2026 Emerging Pharma Leaders were in the studio this week, filming a Peer Exchange with Pharmaceutical Executive.

Congrats to Sarah Ghosh, Nick Botwood, Rena Denoncourt, Christopher Savage & Abid Rahman!

Stay tuned for the full conversation!

#EmergingPharmaLeaders #PharmExec

[Pharmaceutical Executive @PharmExec]

MFPs are now in effect, and manufacturers have little time to get effectuation right. Get practical guidance on MFP compliance, drawn from direct engagement with CMS.

Register now: https://t.co/Kr6bxAODTS

[Pharmaceutical Executive @PharmExec]

As therapies move from the clinic to the home, patient confidence is critical to success. Discover how human factors, training, and ongoing support can help drive long-term adherence. #PatientSupport
https://t.co/3idN3sy1jG

[Pharmaceutical Executive @PharmExec]

China's biotech licensing deals hit $51.9 billion in 2024, up 90% year over year.

Dr. Ying Huang, CEO of K2 Therapeutics, on what's fueling the shift.

🔗 Watch more: https://t.co/GJUrS2qNny

#PharmExec #Biotech

[Pharmaceutical Executive @PharmExec]

Agentic AI is reshaping the specialty pharmacy experience. Explore how Gifthealth combines intelligent automation with human expertise to streamline the prescription journey while keeping empathy, clinical judgment, and trust at the center. #HealthTech
https://t.co/Whh5SUZomX

[Pharmaceutical Executive @PharmExec]

As specialty therapies become more complex, patient support must evolve beyond individual services. Discover how connected technology and human engagement can create a more coordinated, personalized patient experience. #PatientSupport
https://t.co/ILaeK56xNB

[Pharmaceutical Executive @PharmExec]

An executive order can cut drug prices today & get undone tomorrow.

Joe Cunningham says the new MFN deals are a good first step, but without Congress behind them, they only touch Medicaid, leaving the commercial market, about 80% of Americans, untouched.

#PharmExec #DrugPricing

[Pharmaceutical Executive @PharmExec]

Onshoring pledges & a shifting FDA pricing conversation are reshaping how pharma leaders plan ahead.

Latest Fault Lines Peer Exchange: https://t.co/rV0ad0ccVd
#PharmaExec

[Pharmaceutical Executive @PharmExec]

Real-world data used to be a nice-to-have in pharma research.

Mark Cziraky, President of Carelon Research, says that's changing fast.

🔗 Watch the full conversation: https://t.co/lcAHnN0q9N

#PharmExec #RealWorldData

[Pharmaceutical Executive @PharmExec]

Eli Lilly leads the 2026 Pharm Exec Top 50 for the first time ever.

See how the rest of the top 10 stacks up.

🔗 Full rankings: https://t.co/lc2J3tTsgo

#PharmExec #PharmaTop50

[Pharmaceutical Executive @PharmExec]

If the FDA restricts compounded peptides without a clear regulated pathway, where does that demand actually go?

Nate Hill, CEO of Strive Pharmacy, on the gray market's biggest blind spot.

Watch part one➡️ https://t.co/eF4yfQ65EK

#PharmExec #Peptides #Compounding

[Pharmaceutical Executive @PharmExec]

Licensing commitments with Chinese companies hit a record $51.9B in 2024, up 90% in a single year.

K2 Therapeutics CEO Ying Huang on the two forces that made the shift permanent: https://t.co/omPdAsVeuZ

#PharmExec #Biotech

[Pharmaceutical Executive @PharmExec]

What's pushing doctors out of clinical practice before 50? New research in The Permanente Journal offers the clearest picture in over a decade, and points to a factor the burnout conversation keeps missing.

https://t.co/WNvVBX7u1D

#PhysicianBurnout #ClinicalPractice

[Pharmaceutical Executive @PharmExec]

Peter Friedman (LiveWorld) on why human-led AI is essential for pharma navigating hallucination risk and regulatory scrutiny, and how curated data plus human expertise turns raw information into decision-grade insight.

https://t.co/6U2nFutwut

#AIinPharma #LiveWorld

[Pharmaceutical Executive @PharmExec]

An FDA panel just recommended six peptides for the compounding Bulks List.

James LaValle says that is not approval, & the real fight is over evidence & oversight.

🔗 Full Q&A: https://t.co/VhgMidTev6

#PharmExec #PeptideTherapy

[Pharmaceutical Executive @PharmExec]

Only 9% of the API used in U.S. drugs is actually made here, even though generics fill about 90% of prescriptions.

Rohit Tripathi explains why reshoring pharma takes more than a new factory.

🔗 Full Q&A: https://t.co/6gS96ptqZr

#PharmExec #Reshoring

[Pharmaceutical Executive @PharmExec]

Real-world data is reshaping clinical trials — but the richest insights are often locked in unstructured clinical notes. See how AI is changing that. New research from Tufts CSDD

Register now: https://t.co/Ycq9cgcerb